{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:34:21Z","timestamp":1794004461679,"version":"4.8.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Swiss National Foundation","award":["320030_220229"],"award-info":[{"award-number":["320030_220229"]}]},{"name":"the Swiss National Foundation","award":["320030_220229"],"award-info":[{"award-number":["320030_220229"]}]},{"DOI":"10.13039\/100008273","name":"the Novartis Foundation","doi-asserted-by":"crossref","award":["23C192"],"award-info":[{"award-number":["23C192"]}],"id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01184-z","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T17:59:13Z","timestamp":1755280753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development"],"prefix":"10.1038","volume":"10","author":[{"given":"Amanda Makha","family":"Bifani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Kang","family":"Tee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Antanasijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Tapparel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"1184_CR1","doi-asserted-by":"crossref","unstructured":"Brouwer, L., Moreni, G., Wolthers, K.C. & Pajkrt, D. World-wide prevalence and genotype distribution of enteroviruses. Viruses 13, 434 (2021).","DOI":"10.3390\/v13030434"},{"key":"1184_CR2","doi-asserted-by":"crossref","unstructured":"Royston, L. & Tapparel, C. Rhinoviruses and respiratory enteroviruses: not as simple as ABC. Viruses 8, 16 (2016).","DOI":"10.3390\/v8010016"},{"key":"1184_CR3","doi-asserted-by":"crossref","unstructured":"Xie, Z., Khamrin, P., Maneekarn, N. & Kumthip, K. Epidemiology of enterovirus genotypes in association with human diseases. Viruses 16, 1165 (2024).","DOI":"10.3390\/v16071165"},{"key":"1184_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.meegid.2012.10.016","volume":"14","author":"C Tapparel","year":"2013","unstructured":"Tapparel, C., Siegrist, F., Petty, T. J. & Kaiser, L. Picornavirus and enterovirus diversity with associated human diseases. Infect. Genet. Evol. 14, 282\u2013293 (2013).","journal-title":"Infect. Genet. Evol."},{"key":"1184_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04604-x","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. A novel subgenotype C6 Enterovirus A71 originating from the recombination between subgenotypes C4 and C2 strains in mainland China. Sci. Rep. 12, 593 (2022).","journal-title":"Sci. Rep."},{"key":"1184_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.meegid.2009.05.010","volume":"10","author":"YF Chan","year":"2010","unstructured":"Chan, Y. F., Sam, I. C. & AbuBakar, S. Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences. Infect. Genet. Evol. 10, 404\u2013412 (2010).","journal-title":"Infect. Genet. Evol."},{"key":"1184_CR7","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00430-016-0465-y","volume":"205","author":"S Aswathyraj","year":"2016","unstructured":"Aswathyraj, S., Arunkumar, G., Alidjinou, E. K. & Hober, D. Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy. Med. Microbiol. Immunol. 205, 397\u2013407 (2016).","journal-title":"Med. Microbiol. Immunol."},{"key":"1184_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.coviro.2021.10.006","volume":"51","author":"KA Huang","year":"2021","unstructured":"Huang, K. A. Structural basis for neutralization of enterovirus. Curr. Opin. Virol. 51, 199\u2013206 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"1184_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1128\/JVI.00069-11","volume":"86","author":"CC Kok","year":"2012","unstructured":"Kok, C. C., Phuektes, P., Bek, E. & McMinn, P. C. Modification of the untranslated regions of human enterovirus 71 impairs growth in a cell-specific manner. J. Virol. 86, 542\u2013552 (2012).","journal-title":"J. Virol."},{"key":"1184_CR10","doi-asserted-by":"publisher","first-page":"e0144208","DOI":"10.1371\/journal.pone.0144208","volume":"10","author":"J Du","year":"2015","unstructured":"Du, J. et al. Analysis of enterovirus 68 strains from the 2014 North American outbreak reveals a new clade, indicating viral evolution. PLoS ONE 10, e0144208 (2015).","journal-title":"PLoS ONE"},{"key":"1184_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19013-3","volume":"11","author":"KA Huang","year":"2020","unstructured":"Huang, K. A. et al. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nat. Commun. 11, 5253 (2020).","journal-title":"Nat. Commun."},{"key":"1184_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.1218713","volume":"336","author":"P Plevka","year":"2012","unstructured":"Plevka, P., Perera, R., Cardosa, J., Kuhn, R. J. & Rossmann, M. G. Crystal structure of human enterovirus 71. Science 336, 1274 (2012).","journal-title":"Science"},{"key":"1184_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1007\/s13238-014-0087-3","volume":"5","author":"M Dang","year":"2014","unstructured":"Dang, M. et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell 5, 692\u2013703 (2014).","journal-title":"Protein Cell"},{"key":"1184_CR14","doi-asserted-by":"publisher","first-page":"12084","DOI":"10.1128\/JVI.02189-15","volume":"89","author":"Z Ku","year":"2015","unstructured":"Ku, Z. et al. Single Neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J. Virol. 89, 12084\u201312095 (2015).","journal-title":"J. Virol."},{"key":"1184_CR15","doi-asserted-by":"publisher","first-page":"e01013","DOI":"10.1128\/mBio.01013-18","volume":"9","author":"L Zhu","year":"2018","unstructured":"Zhu, L. et al. Neutralization mechanisms of two highly potent antibodies against human enterovirus 71. mBio 9, e01013\u201318 (2018).","journal-title":"mBio"},{"key":"1184_CR16","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1074\/jbc.M114.624536","volume":"290","author":"K Lyu","year":"2015","unstructured":"Lyu, K. et al. Crystal structures of enterovirus 71 (EV71) recombinant virus particles provide insights into vaccine design. J. Biol. Chem. 290, 3198\u20133208 (2015).","journal-title":"J. Biol. Chem."},{"key":"1184_CR17","doi-asserted-by":"publisher","first-page":"e2895","DOI":"10.1371\/journal.pntd.0002895","volume":"8","author":"TK Kiener","year":"2014","unstructured":"Kiener, T. K., Jia, Q., Meng, T., Chow, V. T. & Kwang, J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved \u201cknob\u201d region of VP3 protein. PLoS Negl. Trop. Dis. 8, e2895 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1184_CR18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41579-018-0005-4","volume":"16","author":"J Baggen","year":"2018","unstructured":"Baggen, J., Thibaut, H. J., Strating, J. & van Kuppeveld, F. J. M. The life cycle of non-polio enteroviruses and how to target it. Nat. Rev. Microbiol. 16, 368\u2013381 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"1184_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.49","volume":"3","author":"S Yamayoshi","year":"2014","unstructured":"Yamayoshi, S., Fujii, K. & Koike, S. Receptors for enterovirus 71. Emerg. Microbes Infect. 3, e53 (2014).","journal-title":"Emerg. Microbes Infect."},{"key":"1184_CR20","doi-asserted-by":"crossref","unstructured":"Yuan, M. et al. Enhanced human enterovirus 71 infection by endocytosis inhibitors reveals multiple entry pathways by enterovirus causing hand-foot-and-mouth diseases. Virol. J. 15, 1 (2018).","DOI":"10.1186\/s12985-017-0913-3"},{"key":"1184_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1074\/jbc.M110.168468","volume":"286","author":"KM Hussain","year":"2011","unstructured":"Hussain, K. M., Leong, K. L., Ng, M. M. & Chu, J. J. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J. Biol. Chem. 286, 309\u2013321 (2011).","journal-title":"J. Biol. Chem."},{"key":"1184_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12985-020-01430-x","volume":"17","author":"RO Diarimalala","year":"2020","unstructured":"Diarimalala, R. O., Hu, M., Wei, Y. & Hu, K. Recent advances of enterovirus 71 [Formula: see text] targeting Inhibitors. Virol. J. 17, 173 (2020).","journal-title":"Virol. J."},{"key":"1184_CR23","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0042-6822(03)00544-0","volume":"315","author":"SR Thompson","year":"2003","unstructured":"Thompson, S. R. & Sarnow, P. Enterovirus 71 contains a type I IRES element that functions when eukaryotic initiation factor eIF4G is cleaved. Virology 315, 259\u2013266 (2003).","journal-title":"Virology"},{"key":"1184_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1423-0127-21-14","volume":"21","author":"CW Tan","year":"2014","unstructured":"Tan, C. W., Lai, J. K., Sam, I. C. & Chan, Y. F. Recent developments in antiviral agents against enterovirus 71 infection. J. Biomed. Sci. 21, 14 (2014).","journal-title":"J. Biomed. Sci."},{"key":"1184_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2023.100298","volume":"104","author":"Y Wei","year":"2024","unstructured":"Wei, Y. et al. Recent advances in enterovirus A71 infection and antiviral agents. Lab. Invest. 104, 100298 (2024).","journal-title":"Lab. Invest."},{"key":"1184_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3201\/eid2201.151323","volume":"22","author":"PF Horwood","year":"2016","unstructured":"Horwood, P. F. et al. Seroepidemiology of Human Enterovirus 71 Infection among Children, Cambodia. Emerg. Infect. Dis. 22, 92\u201395 (2016).","journal-title":"Emerg. Infect. Dis."},{"key":"1184_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34992-1","volume":"13","author":"J Yang","year":"2022","unstructured":"Yang, J. et al. Seroepidemiology of enterovirus A71 infection in prospective cohort studies of children in southern China, 2013\u20132018. Nat. Commun. 13, 7280 (2022).","journal-title":"Nat. Commun."},{"key":"1184_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1348-0421.1979.tb00448.x","volume":"23","author":"A Hagiwara","year":"1979","unstructured":"Hagiwara, A., Tagaya, I. & Komatsu, T. Seroepidemiology of enterovirus 71 among healthy children near Tokyo. Microbiol. Immunol. 23, 121\u2013124 (1979).","journal-title":"Microbiol. Immunol."},{"key":"1184_CR29","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1086\/511073","volume":"44","author":"MH Ooi","year":"2007","unstructured":"Ooi, M. H. et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin. Infect. Dis. 44, 646\u2013656 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"1184_CR30","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3201\/eid0809.10.3201\/eid0809.010397","volume":"8","author":"EE Ooi","year":"2002","unstructured":"Ooi, E. E., Phoon, M. C., Ishak, B. & Chan, S. H. Seroepidemiology of human enterovirus 71, Singapore. Emerg. Infect. Dis. 8, 995\u2013997 (2002).","journal-title":"Emerg. Infect. Dis."},{"key":"1184_CR31","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3201\/eid0903.020285","volume":"9","author":"TY Lin","year":"2003","unstructured":"Lin, T. Y., Twu, S. J., Ho, M. S., Chang, L. Y. & Lee, C. Y. Enterovirus 71 outbreaks, Taiwan: occurrence and recognition. Emerg. Infect. Dis. 9, 291\u2013293 (2003).","journal-title":"Emerg. Infect. Dis."},{"key":"1184_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1423-0127-21-16","volume":"21","author":"P Linsuwanon","year":"2014","unstructured":"Linsuwanon, P. et al. Epidemiology and seroepidemiology of human enterovirus 71 among Thai populations. J. Biomed. Sci. 21, 16 (2014).","journal-title":"J. Biomed. Sci."},{"key":"1184_CR33","doi-asserted-by":"publisher","first-page":"e21116","DOI":"10.1371\/journal.pone.0021116","volume":"6","author":"CB Tran","year":"2011","unstructured":"Tran, C. B. et al. The seroprevalence and seroincidence of enterovirus71 infection in infants and children in Ho Chi Minh City, Viet Nam. PLoS ONE 6, e21116 (2011).","journal-title":"PLoS ONE"},{"key":"1184_CR34","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00705-022-05642-0","volume":"168","author":"Y Shi","year":"2023","unstructured":"Shi, Y., Chen, P., Bai, Y., Xu, X. & Liu, Y. Seroprevalence of coxsackievirus A6 and enterovirus A71 infection in humans: a systematic review and meta-analysis. Arch. Virol. 168, 37 (2023).","journal-title":"Arch. Virol."},{"key":"1184_CR35","doi-asserted-by":"publisher","first-page":"e0224110","DOI":"10.1371\/journal.pone.0224110","volume":"14","author":"JT Lee","year":"2019","unstructured":"Lee, J. T. et al. Enterovirus 71 seroepidemiology in Taiwan in 2017 and comparison of those rates in 1997, 1999 and 2007. PLoS ONE 14, e0224110 (2019).","journal-title":"PLoS ONE"},{"key":"1184_CR36","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1542\/peds.109.6.e88","volume":"109","author":"LY Chang","year":"2002","unstructured":"Chang, L. Y. et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease\/herpangina in children during an epidemic in Taiwan. Pediatrics 109, e88 (2002).","journal-title":"Pediatrics"},{"key":"1184_CR37","doi-asserted-by":"publisher","first-page":"106","DOI":"10.47102\/annals-acadmedsg.V38N2p106","volume":"38","author":"LW Ang","year":"2009","unstructured":"Ang, L. W. et al. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann. Acad. Med. Singap. 38, 106\u2013112 (2009).","journal-title":"Ann. Acad. Med. Singap."},{"key":"1184_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/imr.13402","volume":"328","author":"Q Riller","year":"2024","unstructured":"Riller, Q., Schmutz, M., Fourgeaud, J., Fischer, A. & Neven, B. Protective role of antibodies in enteric virus infections: Lessons from primary and secondary immune deficiencies. Immunol. Rev. 328, 243\u2013264 (2024).","journal-title":"Immunol. Rev."},{"key":"1184_CR39","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3201\/eid1908.130202","volume":"19","author":"S Kassab","year":"2013","unstructured":"Kassab, S. et al. Fatal case of enterovirus 71 infection and rituximab therapy, france, 2012. Emerg. Infect. Dis. 19, 1345\u20131347 (2013).","journal-title":"Emerg. Infect. Dis."},{"key":"1184_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1053\/jinf.2002.1066","volume":"46","author":"E Halliday","year":"2003","unstructured":"Halliday, E., Winkelstein, J. & Webster, A. D. Enteroviral infections in primary immunodeficiency (PID): a survey of morbidity and mortality. J. Infect. 46, 1\u20138 (2003).","journal-title":"J. Infect."},{"key":"1184_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jns.2011.03.009","volume":"305","author":"R Ahmed","year":"2011","unstructured":"Ahmed, R. et al. Enterovirus 71 meningoencephalitis complicating rituximab therapy. J. Neurol. Sci. 305, 149\u2013151 (2011).","journal-title":"J. Neurol. Sci."},{"key":"1184_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112389","volume":"42","author":"KF Weng","year":"2023","unstructured":"Weng, K. F. et al. Variant enterovirus A71 found in immune-suppressed patient binds to heparan sulfate and exhibits neurotropism in B-cell-depleted mice. Cell Rep. 42, 112389 (2023).","journal-title":"Cell Rep."},{"key":"1184_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12929-019-0573-2","volume":"26","author":"J Puenpa","year":"2019","unstructured":"Puenpa, J., Wanlapakorn, N., Vongpunsawad, S. & Poovorawan, Y. The history of enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J. Biomed. Sci. 26, 75 (2019).","journal-title":"J. Biomed. Sci."},{"key":"1184_CR44","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","volume":"14","author":"W Xing","year":"2014","unstructured":"Xing, W. et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect. Dis. 14, 308\u2013318 (2014).","journal-title":"Lancet Infect. Dis."},{"key":"1184_CR45","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.4269\/ajtmh.19-0916","volume":"102","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Seasonal Distribution and Meteorological Factors Associated with Hand, Foot, and Mouth Disease among Children in Xi\u2019an, Northwestern China. Am. J. Trop. Med. Hyg. 102, 1253\u20131262 (2020).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"1184_CR46","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jcv.2011.12.025","volume":"53","author":"M Zeng","year":"2012","unstructured":"Zeng, M. et al. Seroepidemiology of Enterovirus 71 infection prior to the 2011 season in children in Shanghai. J. Clin. Virol. 53, 285\u2013289 (2012).","journal-title":"J. Clin. Virol."},{"key":"1184_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-11-270","volume":"11","author":"LW Ang","year":"2011","unstructured":"Ang, L. W. et al. The changing seroepidemiology of enterovirus 71 infection among children and adolescents in Singapore. BMC Infect. Dis. 11, 270 (2011).","journal-title":"BMC Infect. Dis."},{"key":"1184_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jcv.2018.01.008","volume":"101","author":"H Harvala","year":"2018","unstructured":"Harvala, H. et al. Recommendations for enterovirus diagnostics and characterisation within and beyond Europe. J. Clin. Virol. 101, 11\u201317 (2018).","journal-title":"J. Clin. Virol."},{"key":"1184_CR49","unstructured":"Organization, T.W.H. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD), (World Health Organization, Manila, Philippines, 2011)."},{"key":"1184_CR50","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.virs.2022.11.004","volume":"38","author":"Y Zhou","year":"2023","unstructured":"Zhou, Y. et al. Diagnostic performance of different specimens in detecting enterovirus A71 in children with hand, foot and mouth disease. Virol. Sin. 38, 268\u2013275 (2023).","journal-title":"Virol. Sin."},{"key":"1184_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/jmv.25672","volume":"92","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. J. Med. Virol. 92, 1059\u20131064 (2020).","journal-title":"J. Med. Virol."},{"key":"1184_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3274-7","volume":"18","author":"THT Nguyen","year":"2018","unstructured":"Nguyen, T. H. T. et al. Methods to discriminate primary from secondary dengue during acute symptomatic infection. BMC Infect. Dis. 18, 375 (2018).","journal-title":"BMC Infect. Dis."},{"key":"1184_CR53","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1128\/JCM.01394-06","volume":"45","author":"MH Ooi","year":"2007","unstructured":"Ooi, M. H. et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. J. Clin. Microbiol. 45, 1858\u20131866 (2007).","journal-title":"J. Clin. Microbiol."},{"key":"1184_CR54","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S1474-4422(10)70209-X","volume":"9","author":"MH Ooi","year":"2010","unstructured":"Ooi, M. H., Wong, S. C., Lewthwaite, P., Cardosa, M. J. & Solomon, T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 9, 1097\u20131105 (2010).","journal-title":"Lancet Neurol."},{"key":"1184_CR55","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","volume":"26","author":"PC McMinn","year":"2002","unstructured":"McMinn, P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91\u2013107 (2002).","journal-title":"FEMS Microbiol. Rev."},{"key":"1184_CR56","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/INF.0b013e3182116e95","volume":"30","author":"E Ma","year":"2011","unstructured":"Ma, E. et al. Estimation of the basic reproduction number of enterovirus 71 and coxsackievirus A16 in hand, foot, and mouth disease outbreaks. Pediatr. Infect. Dis. J. 30, 675\u2013679 (2011).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1184_CR57","first-page":"11608","volume":"8","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. Relationship between serologic response and clinical symptoms in children with enterovirus 71-infected hand-foot-mouth disease. Int. J. Clin. Exp. Pathol. 8, 11608\u201311614 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"1184_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-417","volume":"14","author":"HY Cheng","year":"2014","unstructured":"Cheng, H. Y. et al. The correlation between the presence of viremia and clinical severity in patients with enterovirus 71 infection: a multi-center cohort study. BMC Infect. Dis. 14, 417 (2014).","journal-title":"BMC Infect. Dis."},{"key":"1184_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103398","volume":"68","author":"Q Qiu","year":"2021","unstructured":"Qiu, Q. et al. Kinetics of the neutralising antibody response in patients with hand, foot, and mouth disease caused by EV-A71: a longitudinal cohort study in Zhengzhou during 2017-2019. EBioMedicine 68, 103398 (2021).","journal-title":"EBioMedicine"},{"key":"1184_CR60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.4049\/jimmunol.2200143","volume":"209","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Comparison of neutralizing antibody response kinetics in patients with hand, foot, and mouth disease caused by coxsackievirus A16 or enterovirus A71: a longitudinal cohort study of Chinese Children, 2017\u20132019. J. Immunol. 209, 280\u2013287 (2022).","journal-title":"J. Immunol."},{"key":"1184_CR61","doi-asserted-by":"publisher","first-page":"e11388","DOI":"10.1371\/journal.pone.0011388","volume":"5","author":"F Xu","year":"2010","unstructured":"Xu, F. et al. Performance of detecting IgM antibodies against enterovirus 71 for early diagnosis. PLoS ONE 5, e11388 (2010).","journal-title":"PLoS ONE"},{"key":"1184_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41577-019-0261-1","volume":"20","author":"K Chen","year":"2020","unstructured":"Chen, K., Magri, G., Grasset, E. K. & Cerutti, A. Rethinking mucosal antibody responses: IgM, IgG and IgD join IgA. Nat. Rev. Immunol. 20, 427\u2013441 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1184_CR63","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1304923","volume":"370","author":"F Zhu","year":"2014","unstructured":"Zhu, F. et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N. Engl. J. Med. 370, 818\u2013828 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1184_CR64","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(22)00313-0","volume":"399","author":"TT Nguyen","year":"2022","unstructured":"Nguyen, T. T. et al. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet 399, 1708\u20131717 (2022).","journal-title":"Lancet"},{"key":"1184_CR65","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1080\/21645515.2015.1053675","volume":"11","author":"S Sun","year":"2015","unstructured":"Sun, S. et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum. Vaccin Immunother. 11, 2406\u20132413 (2015).","journal-title":"Hum. Vaccin Immunother."},{"key":"1184_CR66","doi-asserted-by":"publisher","first-page":"6017","DOI":"10.1016\/j.vaccine.2015.05.108","volume":"33","author":"PY Lim","year":"2015","unstructured":"Lim, P. Y. et al. Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 33, 6017\u20136024 (2015).","journal-title":"Vaccine"},{"key":"1184_CR67","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00281-021-00879-4","volume":"43","author":"C Seikrit","year":"2021","unstructured":"Seikrit, C. & Pabst, O. The immune landscape of IgA induction in the gut. Semin. Immunopathol. 43, 627\u2013637 (2021).","journal-title":"Semin. Immunopathol."},{"key":"1184_CR68","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4161\/gmic.2.5.18269","volume":"2","author":"A Mathias","year":"2011","unstructured":"Mathias, A. & Corthesy, B. N-Glycans on secretory component: mediators of the interaction between secretory IgA and gram-positive commensals sustaining intestinal homeostasis. Gut Microbes 2, 287\u2013293 (2011).","journal-title":"Gut Microbes"},{"key":"1184_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.70004","volume":"34","author":"CJ Mbani","year":"2024","unstructured":"Mbani, C. J. et al. Enterovirus antibodies: friends and foes. Rev. Med. Virol. 34, e70004 (2024).","journal-title":"Rev. Med. Virol."},{"key":"1184_CR70","doi-asserted-by":"publisher","first-page":"e1005454","DOI":"10.1371\/journal.ppat.1005454","volume":"12","author":"X Ye","year":"2016","unstructured":"Ye, X. et al. Structural basis for recognition of human enterovirus 71 by a bivalent broadly neutralizing monoclonal antibody. PLoS Pathog. 12, e1005454 (2016).","journal-title":"PLoS Pathog."},{"key":"1184_CR71","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1073\/pnas.1320624111","volume":"111","author":"P Plevka","year":"2014","unstructured":"Plevka, P. et al. Neutralizing antibodies can initiate genome release from human enterovirus 71. Proc. Natl. Acad. Sci. USA 111, 2134\u20132139 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1184_CR72","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1128\/jvi.59.2.479-485.1986","volume":"59","author":"AA Thomas","year":"1986","unstructured":"Thomas, A. A., Vrijsen, R. & Boeye, A. Relationship between poliovirus neutralization and aggregation. J. Virol. 59, 479\u2013485 (1986).","journal-title":"J. Virol."},{"key":"1184_CR73","doi-asserted-by":"publisher","first-page":"e1005253","DOI":"10.1371\/journal.ppat.1005253","volume":"11","author":"RE Watkinson","year":"2015","unstructured":"Watkinson, R. E., McEwan, W. A., Tam, J. C., Vaysburd, M. & James, L. C. TRIM21 promotes cGAS and RIG-I sensing of viral genomes during infection by antibody-opsonized virus. PLoS Pathog. 11, e1005253 (2015).","journal-title":"PLoS Pathog."},{"key":"1184_CR74","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2149352","volume":"12","author":"R Du","year":"2023","unstructured":"Du, R. et al. Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism. Emerg. Microbes Infect. 12, 2149352 (2023).","journal-title":"Emerg. Microbes Infect."},{"key":"1184_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66600-x","volume":"10","author":"MA Behzadi","year":"2020","unstructured":"Behzadi, M. A. et al. A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro. Sci. Rep. 10, 9750 (2020).","journal-title":"Sci. Rep."},{"key":"1184_CR76","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1743-422X-9-26","volume":"9","author":"F Gao","year":"2012","unstructured":"Gao, F. et al. Enterovirus 71 viral capsid protein linear epitopes: identification and characterization. Virol. J. 9, 26 (2012).","journal-title":"Virol. J."},{"key":"1184_CR77","doi-asserted-by":"publisher","first-page":"e0165659","DOI":"10.1371\/journal.pone.0165659","volume":"11","author":"KL Aw-Yong","year":"2016","unstructured":"Aw-Yong, K. L., Sam, I. C., Koh, M. T. & Chan, Y. F. Immunodominant IgM and IgG epitopes recognized by antibodies induced in enterovirus A71-associated hand, foot and mouth disease patients. PLoS ONE 11, e0165659 (2016).","journal-title":"PLoS ONE"},{"key":"1184_CR78","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcv.2018.06.001","volume":"105","author":"H Zhang","year":"2018","unstructured":"Zhang, H. et al. Genome-wide linear B-cell epitopes of enterovirus 71 in a hand, foot and mouth disease (HFMD) population. J. Clin. Virol. 105, 41\u201348 (2018).","journal-title":"J. Clin. Virol."},{"key":"1184_CR79","doi-asserted-by":"publisher","first-page":"498","DOI":"10.7150\/thno.7457","volume":"4","author":"L Xu","year":"2014","unstructured":"Xu, L. et al. Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop. Theranostics 4, 498\u2013513 (2014).","journal-title":"Theranostics"},{"key":"1184_CR80","doi-asserted-by":"publisher","first-page":"e2073","DOI":"10.1002\/rmv.2073","volume":"29","author":"KL Aw-Yong","year":"2019","unstructured":"Aw-Yong, K. L., NikNadia, N. M. N., Tan, C. W., Sam, I. C. & Chan, Y. F. Immune responses against enterovirus A71 infection: implications for vaccine success. Rev. Med. Virol. 29, e2073 (2019).","journal-title":"Rev. Med. Virol."},{"key":"1184_CR81","unstructured":"Protein Data Bank. https:\/\/www.rcsb.org\/search?request=%7B%22query%22%3A%7B%22type%22%3A%22group%22%2C%22nodes%22%3A%5B%7B%22type%22%3A%22group%22%2C%22nodes%22%3A%5B%7B%22type%22A71%20FAB%22%7D%7D%5D%2C%22logical_operator%22%3A%22and%22%7D%5D%2C%22logical_operator%22%3A%22and%22%2C%22label%22%3A%22full_text%22%7D%5D (2025)."},{"key":"1184_CR82","doi-asserted-by":"publisher","first-page":"e1011420","DOI":"10.1371\/journal.ppat.1011420","volume":"19","author":"L You","year":"2023","unstructured":"You, L. et al. Antibody signatures in hospitalized hand, foot and mouth disease patients with acute enterovirus A71 infection. PLoS Pathog. 19, e1011420 (2023).","journal-title":"PLoS Pathog."},{"key":"1184_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84891-6","volume":"11","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Bioinformatics-based prediction of conformational epitopes for Enterovirus A71 and Coxsackievirus A16. Sci. Rep. 11, 5701 (2021).","journal-title":"Sci. Rep."},{"key":"1184_CR84","doi-asserted-by":"crossref","unstructured":"Saarinen, N.V.V. et al. Multiplexed high-throughput serological assay for human enteroviruses. Microorganisms 8, 1426 (2020).","DOI":"10.3390\/microorganisms8091426"},{"key":"1184_CR85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2017.04.008","volume":"83","author":"A Vatti","year":"2017","unstructured":"Vatti, A. et al. Original antigenic sin: a comprehensive review. J. Autoimmun. 83, 12\u201321 (2017).","journal-title":"J. Autoimmun."},{"key":"1184_CR86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S1386-6532(00)00123-2","volume":"19","author":"H Tsuchiya","year":"2000","unstructured":"Tsuchiya, H., Furukawa, M., Matsui, M., Katsuki, K. & Inouye, S. Original antigenic sin\u2019 phenomenon in neutralizing antibody responses in children with enterovirus meningitis. J. Clin. Virol. 19, 205\u2013207 (2000).","journal-title":"J. Clin. Virol."},{"key":"1184_CR87","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1743-422X-8-106","volume":"8","author":"JF Han","year":"2011","unstructured":"Han, J. F. et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol. J. 8, 106 (2011).","journal-title":"Virol. J."},{"key":"1184_CR88","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/icb.1964.44","volume":"42","author":"RA Hawkes","year":"1964","unstructured":"Hawkes, R. A. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42, 465\u2013482 (1964).","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"1184_CR89","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0065-3527(03)60011-4","volume":"60","author":"SB Halstead","year":"2003","unstructured":"Halstead, S. B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60, 421\u2013467 (2003).","journal-title":"Adv. Virus Res."},{"key":"1184_CR90","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/rmv.405","volume":"13","author":"A Takada","year":"2003","unstructured":"Takada, A. & Kawaoka, Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13, 387\u2013398 (2003).","journal-title":"Rev. Med. Virol."},{"key":"1184_CR91","doi-asserted-by":"publisher","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","volume":"10","author":"R Shukla","year":"2020","unstructured":"Shukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R. & Khanna, N. Antibody-dependent enhancement: a challenge for developing a safe dengue vaccine. Front. Cell Infect. Microbiol. 10, 572681 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1184_CR92","doi-asserted-by":"publisher","first-page":"580096","DOI":"10.3389\/fcimb.2020.580096","volume":"10","author":"R Narayan","year":"2020","unstructured":"Narayan, R. & Tripathi, S. Intrinsic ADE: the dark side of antibody dependent enhancement during dengue infection. Front. Cell Infect. Microbiol. 10, 580096 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1184_CR93","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.molimm.2022.11.010","volume":"152","author":"S Thomas","year":"2022","unstructured":"Thomas, S. et al. Antibody-dependent enhancement (ADE) and the role of complement system in disease pathogenesis. Mol. Immunol. 152, 172\u2013182 (2022).","journal-title":"Mol. Immunol."},{"key":"1184_CR94","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0952-7915(99)80008-9","volume":"11","author":"A Nicholson-Weller","year":"1999","unstructured":"Nicholson-Weller, A. & Klickstein, L. B. C1q-binding proteins and C1q receptors. Curr. Opin. Immunol. 11, 42\u201346 (1999).","journal-title":"Curr. Opin. Immunol."},{"key":"1184_CR95","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1128\/JVI.76.6.2827-2834.2002","volume":"76","author":"C Guillon","year":"2002","unstructured":"Guillon, C., Schutten, M., Boers, P. H., Gruters, R. A. & Osterhaus, A. D. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J. Virol. 76, 2827\u20132834 (2002).","journal-title":"J. Virol."},{"key":"1184_CR96","doi-asserted-by":"crossref","unstructured":"Hu, K., Onintsoa Diarimalala, R., Yao, C., Li, H. & Wei, Y. EV-A71 mechanism of entry: receptors\/co-receptors, related pathways and inhibitors. Viruses 15, 785 (2023).","DOI":"10.3390\/v15030785"},{"key":"1184_CR97","doi-asserted-by":"publisher","first-page":"e1009507","DOI":"10.1371\/journal.ppat.1009507","volume":"17","author":"Y He","year":"2021","unstructured":"He, Y. et al. Structures of foot-and-mouth disease virus with neutralizing antibodies derived from recovered natural host reveal a mechanism for cross-serotype neutralization. PLoS Pathog. 17, e1009507 (2021).","journal-title":"PLoS Pathog."},{"key":"1184_CR98","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1128\/CVI.00108-10","volume":"17","author":"SM Wang","year":"2010","unstructured":"Wang, S. M. et al. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin. Vaccin. Immunol. 17, 1517\u20131523 (2010).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1184_CR99","doi-asserted-by":"crossref","unstructured":"Coudere, K. et al. Neutralising antibodies against enterovirus and parechovirus in IVIG reflect general circulation: a tool for sero-surveillance. Viruses 13, 1028 (2021).","DOI":"10.3390\/v13061028"},{"key":"1184_CR100","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1086\/649012","volume":"50","author":"R Cao","year":"2010","unstructured":"Cao, R. et al. Presence of high-titer neutralizing antibodies against enterovirus 71 in intravenous immunoglobulin manufactured from Chinese donors. Clin. Infect. Dis. 50, 125\u2013126 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"1184_CR101","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00430-013-0289-y","volume":"202","author":"IC Chen","year":"2013","unstructured":"Chen, I. C., Wang, S. M., Yu, C. K. & Liu, C. C. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med. Microbiol. Immunol. 202, 259\u2013265 (2013).","journal-title":"Med. Microbiol. Immunol."},{"key":"1184_CR102","doi-asserted-by":"publisher","first-page":"e64024","DOI":"10.1371\/journal.pone.0064024","volume":"8","author":"RY Cao","year":"2013","unstructured":"Cao, R. Y. et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS ONE 8, e64024 (2013).","journal-title":"PLoS ONE"},{"key":"1184_CR103","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.micinf.2009.01.005","volume":"11","author":"P Sauter","year":"2009","unstructured":"Sauter, P. & Hober, D. Mechanisms and results of the antibody-dependent enhancement of viral infections and role in the pathogenesis of coxsackievirus B-induced diseases. Microbes Infect. 11, 443\u2013451 (2009).","journal-title":"Microbes Infect."},{"key":"1184_CR104","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/21505594.2016.1152442","volume":"7","author":"F Elmastour","year":"2016","unstructured":"Elmastour, F. et al. Immunoglobulin G-dependent enhancement of the infection with Coxsackievirus B4 in a murine system. Virulence 7, 527\u2013535 (2016).","journal-title":"Virulence"},{"key":"1184_CR105","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1006\/jmcc.2002.2087","volume":"34","author":"C Kishimoto","year":"2002","unstructured":"Kishimoto, C., Kurokawa, M. & Ochiai, H. Antibody-mediated immune enhancement in coxsackievirus B3 myocarditis. J. Mol. Cell Cardiol. 34, 1227\u20131238 (2002).","journal-title":"J. Mol. Cell Cardiol."},{"key":"1184_CR106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1054-8807(98)00025-8","volume":"8","author":"JZ Yu","year":"1999","unstructured":"Yu, J. Z. et al. Secondary heterotypic versus homotypic infection by Coxsackie B group viruses: impact on early and late histopathological lesions and virus genome prominence. Cardiovasc. Pathol. 8, 93\u2013102 (1999).","journal-title":"Cardiovasc. Pathol."},{"key":"1184_CR107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.micpath.2018.08.064","volume":"125","author":"S Aswathyraj","year":"2018","unstructured":"Aswathyraj, S. et al. Serum-derived IgG from coxsackievirus A6-infected patients can enhance the infection of peripheral blood mononuclear cells with coxsackievirus A6. Microb. Pathog. 125, 7\u201311 (2018).","journal-title":"Microb. Pathog."},{"key":"1184_CR108","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1099\/0022-1317-82-8-1899","volume":"82","author":"W Chehadeh","year":"2001","unstructured":"Chehadeh, W., Bouzidi, A., Alm, G., Wattre, P. & Hober, D. Human antibodies isolated from plasma by affinity chromatography increase the coxsackievirus B4-induced synthesis of interferon-alpha by human peripheral blood mononuclear cells in vitro. J. Gen. Virol. 82, 1899\u20131907 (2001).","journal-title":"J. Gen. Virol."},{"key":"1184_CR109","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1016\/j.jmb.2013.10.008","volume":"425","author":"EK Alidjinou","year":"2013","unstructured":"Alidjinou, E. K., Sane, F., Engelmann, I. & Hober, D. Serum-dependent enhancement of coxsackievirus B4-induced production of IFNalpha, IL-6 and TNFalpha by peripheral blood mononuclear cells. J. Mol. Biol. 425, 5020\u20135031 (2013).","journal-title":"J. Mol. Biol."},{"key":"1184_CR110","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29399","volume":"96","author":"C Morvan","year":"2024","unstructured":"Morvan, C., Nekoua, M. P., Debuysschere, C., Alidjinou, E. K. & Hober, D. Antibody-dependent enhancement and neutralization against CVB4 investigated in vitro and in silico through an agent-based model. J. Med. Virol. 96, e29399 (2024).","journal-title":"J. Med. Virol."},{"key":"1184_CR111","doi-asserted-by":"publisher","first-page":"4610","DOI":"10.1128\/JVI.72.6.4610-4622.1998","volume":"72","author":"Z Che","year":"1998","unstructured":"Che, Z. et al. Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J. Virol. 72, 4610\u20134622 (1998).","journal-title":"J. Virol."},{"key":"1184_CR112","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000496926","volume":"28","author":"W Jiao","year":"2019","unstructured":"Jiao, W. et al. The effectiveness of different doses of intravenous immunoglobulin on severe hand, foot and mouth disease: a meta-analysis. Med. Princ. Pract. 28, 256\u2013263 (2019).","journal-title":"Med. Princ. Pract."},{"key":"1184_CR113","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1303224","volume":"370","author":"R Li","year":"2014","unstructured":"Li, R. et al. An inactivated enterovirus 71 vaccine in healthy children. N. Engl. J. Med. 370, 829\u2013837 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1184_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0448-7","volume":"13","author":"L Liu","year":"2015","unstructured":"Liu, L. et al. Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations. BMC Med. 13, 226 (2015).","journal-title":"BMC Med."},{"key":"1184_CR115","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","volume":"14","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum. Vaccin. Immunother. 14, 1517\u20131523 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1184_CR116","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/S0140-6736(13)61049-1","volume":"381","author":"FC Zhu","year":"2013","unstructured":"Zhu, F. C. et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 381, 2024\u20132032 (2013).","journal-title":"Lancet"},{"key":"1184_CR117","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1080\/21645515.2019.1709353","volume":"16","author":"T Yang","year":"2020","unstructured":"Yang, T. et al. Safety and immunogenicity of an experimental live combination vaccine against enterovirus 71 and coxsackievirus A16 in rhesus monkeys. Hum. Vaccin. Immunother. 16, 1586\u20131594 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1184_CR118","doi-asserted-by":"publisher","first-page":"e0210477","DOI":"10.1371\/journal.pone.0210477","volume":"14","author":"HJ Kim","year":"2019","unstructured":"Kim, H. J. et al. Efficient expression of enterovirus 71 based on virus-like particles vaccine. PLoS ONE 14, e0210477 (2019).","journal-title":"PLoS ONE"},{"key":"1184_CR119","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1016\/j.vaccine.2024.04.087","volume":"42","author":"A Maje Bello","year":"2024","unstructured":"Maje Bello, A., Chaimongkolnukul, K., Poomputsa, K., Mekvichitsaeng, P. & Maprang Roshorm, Y. Immunogenicity and immunodominant linear B-cell epitopes of a new DNA-based tetravalent vaccine against four major enteroviruses causing hand, foot, and mouth disease. Vaccine 42, 3733\u20133743 (2024).","journal-title":"Vaccine"},{"key":"1184_CR120","doi-asserted-by":"publisher","first-page":"6694","DOI":"10.2174\/1381612822666160720165613","volume":"22","author":"PT Yee","year":"2016","unstructured":"Yee, P. T. & Poh, C. L. Development of novel miRNA-based vaccines and antivirals against enterovirus 71. Curr. Pharm. Des. 22, 6694\u20136700 (2016).","journal-title":"Curr. Pharm. Des."},{"key":"1184_CR121","doi-asserted-by":"crossref","unstructured":"Liu, Z. et al. A novel polypeptide vaccine and adjuvant formulation of EV71. Pathog. Dis. 79, ftab057 (2022).","DOI":"10.1093\/femspd\/ftab057"},{"key":"1184_CR122","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1016\/j.vaccine.2005.12.047","volume":"24","author":"HF Chen","year":"2006","unstructured":"Chen, H. F., Chang, M. H., Chiang, B. L. & Jeng, S. T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24, 2944\u20132951 (2006).","journal-title":"Vaccine"},{"key":"1184_CR123","doi-asserted-by":"crossref","unstructured":"Hu, Q. et al. Effectiveness of EV-A71 vaccine and its impact on the incidence of hand, foot and mouth disease: a systematic review. Vaccines 12, 1028 (2024).","DOI":"10.3390\/vaccines12091028"},{"key":"1184_CR124","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/infdis\/jiw502","volume":"215","author":"M Wei","year":"2017","unstructured":"Wei, M. et al. 2-Year efficacy, immunogenicity, and safety of vigoo enterovirus 71 vaccine in healthy chinese children: a randomized open-label study. J. Infect. Dis. 215, 56\u201363 (2017).","journal-title":"J. Infect. Dis."},{"key":"1184_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11198-6","volume":"21","author":"L Ye","year":"2021","unstructured":"Ye, L. et al. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health 21, 1118 (2021).","journal-title":"BMC Public Health"},{"key":"1184_CR126","doi-asserted-by":"crossref","unstructured":"Zheng, D. et al. Effect of EV71 vaccination on transmission dynamics of hand, foot, and mouth disease and its epidemic prevention threshold. Vaccines 12, 1166 (2024).","DOI":"10.3390\/vaccines12101166"},{"key":"1184_CR127","doi-asserted-by":"crossref","unstructured":"Liu, Y. et al. Effectiveness of the enterovirus A71 vaccine on hand, foot and mouth disease: a real-world study in China. Clin. Microbiol. Infect. 31, 258\u2013265 (2024).","DOI":"10.1016\/j.cmi.2024.09.020"},{"key":"1184_CR128","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/22221751.2021.1899772","volume":"10","author":"H Jiang","year":"2021","unstructured":"Jiang, H. et al. The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China. Emerg. Microbes Infect. 10, 619\u2013628 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"1184_CR129","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-21312-2","volume":"12","author":"M Wang","year":"2022","unstructured":"Wang, M. et al. The spatial-temporal distribution and etiological characteristics of hand-foot-and-mouth disease before and after EV\u2011A71 vaccination in Kunming, China, 2017-2020. Sci. Rep. 12, 17028 (2022).","journal-title":"Sci. Rep."},{"key":"1184_CR130","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.vaccine.2024.02.026","volume":"42","author":"X Duan","year":"2024","unstructured":"Duan, X. et al. Effectiveness of enterovirus A71 vaccine against pediatric HFMD and disease profile of post-vaccination infection. Vaccine 42, 2317\u20132325 (2024).","journal-title":"Vaccine"},{"key":"1184_CR131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2020.02.012","volume":"94","author":"A Lizasoain","year":"2020","unstructured":"Lizasoain, A., Mir, D., Martinez, N. & Colina, R. Coxsackievirus A10 causing hand-foot-and-mouth disease in Uruguay. Int. J. Infect. Dis. 94, 1\u20133 (2020).","journal-title":"Int. J. Infect. Dis."},{"key":"1184_CR132","doi-asserted-by":"publisher","first-page":"e79599","DOI":"10.1371\/journal.pone.0079599","volume":"8","author":"Q Mao","year":"2013","unstructured":"Mao, Q. et al. The cross-neutralizing activity of enterovirus 71 subgenotype c4 vaccines in healthy chinese infants and children. PLoS ONE 8, e79599 (2013).","journal-title":"PLoS ONE"},{"key":"1184_CR133","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1586\/14760584.2016.1096782","volume":"15","author":"JX Li","year":"2016","unstructured":"Li, J. X. et al. Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev. Vaccines 15, 129\u2013137 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"1184_CR134","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.jinf.2020.12.020","volume":"82","author":"H Zeng","year":"2021","unstructured":"Zeng, H. et al. Emergence of a non vaccine-cognate enterovirus A71 genotype C1 in mainland China. J. Infect. 82, 407\u2013413 (2021).","journal-title":"J. Infect."},{"key":"1184_CR135","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jinf.2022.06.020","volume":"85","author":"J Xiao","year":"2022","unstructured":"Xiao, J. et al. The impact of enterovirus A71 vaccination program on hand, foot, and mouth disease in Guangdong, China: a longitudinal surveillance study. J. Infect. 85, 428\u2013435 (2022).","journal-title":"J. Infect."},{"key":"1184_CR136","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1002\/jmv.25657","volume":"92","author":"HB Liu","year":"2020","unstructured":"Liu, H. B. et al. A 5-year molecular epidemiology survey of human enterovirus 71 before vaccine application in Yunnan Province, China. J. Med. Virol. 92, 1085\u20131092 (2020).","journal-title":"J. Med. Virol."},{"key":"1184_CR137","doi-asserted-by":"publisher","first-page":"e79783","DOI":"10.1371\/journal.pone.0079783","volume":"8","author":"AH Chou","year":"2013","unstructured":"Chou, A. H. et al. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers. PLoS ONE 8, e79783 (2013).","journal-title":"PLoS ONE"},{"key":"1184_CR138","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/j.vaccine.2019.02.023","volume":"37","author":"LM Huang","year":"2019","unstructured":"Huang, L. M. et al. Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. Vaccine 37, 1827\u20131835 (2019).","journal-title":"Vaccine"},{"key":"1184_CR139","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1016\/j.vaccine.2013.03.015","volume":"31","author":"A Cheng","year":"2013","unstructured":"Cheng, A. et al. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 31, 2471\u20132476 (2013).","journal-title":"Vaccine"},{"key":"1184_CR140","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4062\/biomolther.2023.058","volume":"31","author":"EJ Yi","year":"2023","unstructured":"Yi, E. J. et al. A bivalent inactivated vaccine prevents enterovirus 71 and coxsackievirus A16 infections in the Mongolian Gerbil. Biomol. Ther.31, 350\u2013358 (2023).","journal-title":"Biomol. Ther."},{"key":"1184_CR141","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/670506","volume":"2014","author":"CW Lin","year":"2014","unstructured":"Lin, C. W. et al. Immunogenicity studies of bivalent inactivated virions of EV71\/CVA16 formulated with submicron emulsion systems. Biomed. Res. Int. 2014, 670506 (2014).","journal-title":"Biomed. Res. Int."},{"key":"1184_CR142","doi-asserted-by":"publisher","first-page":"5919","DOI":"10.3390\/v7112916","volume":"7","author":"EA Caine","year":"2015","unstructured":"Caine, E. A., Fuchs, J., Das, S. C., Partidos, C. D. & Osorio, J. E. Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses 7, 5919\u20135932 (2015).","journal-title":"Viruses"},{"key":"1184_CR143","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/978-3-031-65187-8_21","volume":"105","author":"J Barcena","year":"2024","unstructured":"Barcena, J., Zamora-Ceballos, M. & Blanco, E. Design of novel vaccines based on virus-like particles. Subcell. Biochem. 105, 785\u2013821 (2024).","journal-title":"Subcell. Biochem."},{"key":"1184_CR144","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.1016\/j.vaccine.2013.05.019","volume":"31","author":"HY Li","year":"2013","unstructured":"Li, H. Y., Han, J. F., Qin, C. F. & Chen, R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31, 3281\u20133287 (2013).","journal-title":"Vaccine"},{"key":"1184_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/srep07878","volume":"5","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci. Rep. 5, 7878 (2015).","journal-title":"Sci. Rep."},{"key":"1184_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molimm.2018.09.018","volume":"105","author":"N Issaro","year":"2019","unstructured":"Issaro, N. et al. Induction of immune responses by a novel recombinant fusion protein of enterovirus A71 in BALB\/c mice. Mol. Immunol. 105, 1\u20138 (2019).","journal-title":"Mol. Immunol."},{"key":"1184_CR147","doi-asserted-by":"publisher","first-page":"e21757","DOI":"10.1371\/journal.pone.0021757","volume":"6","author":"T Meng","year":"2011","unstructured":"Meng, T., Kolpe, A. B., Kiener, T. K., Chow, V. T. & Kwang, J. Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice. PLoS ONE 6, e21757 (2011).","journal-title":"PLoS ONE"},{"key":"1184_CR148","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.virusres.2012.06.014","volume":"168","author":"AB Kolpe","year":"2012","unstructured":"Kolpe, A. B., Kiener, T. K., Grotenbreg, G. M. & Kwang, J. Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice. Virus Res. 168, 64\u201372 (2012).","journal-title":"Virus Res."},{"key":"1184_CR149","doi-asserted-by":"crossref","unstructured":"Lin, X. et al. A novel peptide from VP1 of EV-D68 exhibits broad-spectrum antiviral activity against human enteroviruses. Biomolecules 14, 1331 (2024).","DOI":"10.3390\/biom14101331"},{"key":"1184_CR150","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1471-2180-13-287","volume":"13","author":"M Zhao","year":"2013","unstructured":"Zhao, M. et al. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. BMC Microbiol. 13, 287 (2013).","journal-title":"BMC Microbiol."},{"key":"1184_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/srep12973","volume":"5","author":"L Xu","year":"2015","unstructured":"Xu, L. et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci. Rep. 5, 12973 (2015).","journal-title":"Sci. Rep."},{"key":"1184_CR152","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1086\/338819","volume":"34","author":"TY Lin","year":"2002","unstructured":"Lin, T. Y. et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin. Infect. Dis. 34, S52\u201357 (2002).","journal-title":"Clin. Infect. Dis."},{"key":"1184_CR153","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1016\/j.vaccine.2011.04.010","volume":"29","author":"CC Liu","year":"2011","unstructured":"Liu, C. C. et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine 29, 4362\u20134372 (2011).","journal-title":"Vaccine"},{"key":"1184_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41285-z","volume":"9","author":"PTI Yee","year":"2019","unstructured":"Yee, P. T. I. et al. Development of live attenuated Enterovirus 71 vaccine strains that confer protection against lethal challenge in mice. Sci. Rep. 9, 4805 (2019).","journal-title":"Sci. Rep."},{"key":"1184_CR155","doi-asserted-by":"crossref","unstructured":"Chen, N. & Zhang, B. The strategies used by animal viruses to antagonize host antiviral innate immunity: new clues for developing live attenuated vaccines (LAVs). Vaccines (Basel) 13, 46 (2025).","DOI":"10.3390\/vaccines13010046"},{"key":"1184_CR156","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1128\/JVI.02139-12","volume":"87","author":"S Sadeghipour","year":"2013","unstructured":"Sadeghipour, S., Bek, E. J. & McMinn, P. C. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J. Virol. 87, 1759\u20131769 (2013).","journal-title":"J. Virol."},{"key":"1184_CR157","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/nm1726","volume":"14","author":"M Vignuzzi","year":"2008","unstructured":"Vignuzzi, M., Wendt, E. & Andino, R. Engineering attenuated virus vaccines by controlling replication fidelity. Nat. Med. 14, 154\u2013161 (2008).","journal-title":"Nat. Med."},{"key":"1184_CR158","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nature04388","volume":"439","author":"M Vignuzzi","year":"2006","unstructured":"Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344\u2013348 (2006).","journal-title":"Nature"},{"key":"1184_CR159","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.chom.2008.08.003","volume":"4","author":"D Barnes","year":"2008","unstructured":"Barnes, D., Kunitomi, M., Vignuzzi, M., Saksela, K. & Andino, R. Harnessing endogenous miRNAs to control virus tissue tropism as a strategy for developing attenuated virus vaccines. Cell Host Microbe 4, 239\u2013248 (2008).","journal-title":"Cell Host Microbe"},{"key":"1184_CR160","doi-asserted-by":"publisher","first-page":"435","DOI":"10.2217\/imt-2017-0010","volume":"9","author":"EJ Mendoza","year":"2017","unstructured":"Mendoza, E. J., Racine, T. & Kobinger, G. P. The ongoing evolution of antibody-based treatments for Ebola virus infection. Immunotherapy 9, 435\u2013450 (2017).","journal-title":"Immunotherapy"},{"key":"1184_CR161","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1038\/s41564-024-01822-7","volume":"9","author":"R Zhu","year":"2024","unstructured":"Zhu, R. et al. Broadly therapeutic antibody provides cross-serotype protection against enteroviruses via Fc effector functions and by mimicking SCARB2. Nat. Microbiol. 9, 2939\u20132953 (2024).","journal-title":"Nat. Microbiol."},{"key":"1184_CR162","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12865-019-0288-x","volume":"20","author":"Y Li","year":"2019","unstructured":"Li, Y., Yu, J., Qi, X. & Yan, H. Monoclonal antibody against EV71 3D(pol) inhibits the polymerase activity of RdRp and virus replication. BMC Immunol. 20, 6 (2019).","journal-title":"BMC Immunol."},{"key":"1184_CR163","doi-asserted-by":"publisher","first-page":"e109391","DOI":"10.1371\/journal.pone.0109391","volume":"9","author":"Z Li","year":"2014","unstructured":"Li, Z. et al. In vivo time-related evaluation of a therapeutic neutralization monoclonal antibody against lethal enterovirus 71 infection in a mouse model. PLoS ONE 9, e109391 (2014).","journal-title":"PLoS ONE"},{"key":"1184_CR164","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.antiviral.2018.11.001","volume":"161","author":"B Zhou","year":"2019","unstructured":"Zhou, B. et al. A bispecific broadly neutralizing antibody against enterovirus 71 and coxsackievirus A16 with therapeutic potential. Antivir. Res. 161, 28\u201335 (2019).","journal-title":"Antivir. Res."},{"key":"1184_CR165","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/mab.2013.0033","volume":"32","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. Monoclonal antibodies for diagnosis of enterovirus 71. Monoclon. Antib. Immunodiagn. Immunother. 32, 386\u2013394 (2013).","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"1184_CR166","doi-asserted-by":"crossref","unstructured":"Zhang, X. et al. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protein Cell 8, 590\u2013600 (2017).","DOI":"10.1007\/s13238-017-0405-7"},{"key":"1184_CR167","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0022-3476(98)70155-6","volume":"133","author":"LC Lum","year":"1998","unstructured":"Lum, L. C. et al. Fatal enterovirus 71 encephalomyelitis. J. Pediatr. 133, 795\u2013798 (1998).","journal-title":"J. Pediatr."},{"key":"1184_CR168","doi-asserted-by":"publisher","first-page":"e29751","DOI":"10.1371\/journal.pone.0029751","volume":"7","author":"XF Lim","year":"2012","unstructured":"Lim, X. F. et al. Characterization of an isotype-dependent monoclonal antibody against linear neutralizing epitope effective for prophylaxis of enterovirus 71 infection. PLoS ONE 7, e29751 (2012).","journal-title":"PLoS ONE"},{"key":"1184_CR169","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/imm.13629","volume":"169","author":"W Zhu","year":"2023","unstructured":"Zhu, W. et al. Dual blockages of a broad and potent neutralizing IgM antibody targeting GH loop of EV-As. Immunology 169, 292\u2013308 (2023).","journal-title":"Immunology"},{"key":"1184_CR170","doi-asserted-by":"publisher","first-page":"6510","DOI":"10.1016\/j.vaccine.2021.09.056","volume":"39","author":"W Zhu","year":"2021","unstructured":"Zhu, W. et al. A broad and potent IgM antibody against tetra-EV-As induced by EVA71 and CVA16 co-immunization. Vaccine 39, 6510\u20136519 (2021).","journal-title":"Vaccine"},{"key":"1184_CR171","doi-asserted-by":"crossref","unstructured":"Ledford, H. Antibody therapies could be a bridge to a coronavirus vaccine \u2014 but will the world benefit? (Nature, 2020).","DOI":"10.1038\/d41586-020-02360-y"},{"key":"1184_CR172","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/DHPS.S348727","volume":"15","author":"S O\u2019Hagan","year":"2023","unstructured":"O\u2019Hagan, S., Galway, N., Shields, M. D., Mallett, P. & Groves, H. E. Review of the safety, efficacy and tolerability of palivizumab in the prevention of severe respiratory syncytial virus (RSV) disease. Drug Health Patient Saf. 15, 103\u2013112 (2023).","journal-title":"Drug Health Patient Saf."},{"key":"1184_CR173","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2023.01.002","volume":"31","author":"V Rayaprolu","year":"2023","unstructured":"Rayaprolu, V. et al. Structure of the Inmazeb cocktail and resistance to Ebola virus escape. Cell Host Microbe 31, 260\u2013272.e267 (2023).","journal-title":"Cell Host Microbe"},{"key":"1184_CR174","doi-asserted-by":"crossref","unstructured":"Muslin, C., Mac Kain, A., Bessaud, M., Blondel, B. & Delpeyroux, F. Recombination in enteroviruses, a multi-step modular evolutionary process. Viruses 11, 859 (2019).","DOI":"10.3390\/v11090859"},{"key":"1184_CR175","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03660-21","volume":"13","author":"AB Rosenfeld","year":"2022","unstructured":"Rosenfeld, A. B. et al. Cross-Reactive Antibody Responses against Nonpoliovirus Enteroviruses. mBio 13, e0366021 (2022).","journal-title":"mBio"},{"key":"1184_CR176","doi-asserted-by":"publisher","first-page":"e1011616","DOI":"10.1371\/journal.ppat.1011616","volume":"19","author":"AD Wegman","year":"2023","unstructured":"Wegman, A. D. et al. DENV-specific IgA contributes protective and non-pathologic function during antibody-dependent enhancement of DENV infection. PLoS Pathog. 19, e1011616 (2023).","journal-title":"PLoS Pathog."},{"key":"1184_CR177","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41574-022-00688-1","volume":"18","author":"MP Nekoua","year":"2022","unstructured":"Nekoua, M. P., Alidjinou, E. K. & Hober, D. Persistent coxsackievirus B infection and pathogenesis of type 1 diabetes mellitus. Nat. Rev. Endocrinol. 18, 503\u2013516 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1184_CR178","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrendo.2016.30","volume":"12","author":"A Op de Beeck","year":"2016","unstructured":"Op de Beeck, A. & Eizirik, D. L. Viral infections in type 1 diabetes mellitus-why the beta cells?. Nat. Rev. Endocrinol. 12, 263\u2013273 (2016).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1184_CR179","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/jmv.10306","volume":"69","author":"T Harkonen","year":"2003","unstructured":"Harkonen, T. et al. Enterovirus infection may induce humoral immune response reacting with islet cell autoantigens in humans. J. Med. Virol. 69, 426\u2013440 (2003).","journal-title":"J. Med. Virol."},{"key":"1184_CR180","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S1473-3099(19)30566-3","volume":"20","author":"L Bubba","year":"2020","unstructured":"Bubba, L. et al. Circulation of non-polio enteroviruses in 24 EU and EEA countries between 2015 and 2017: a retrospective surveillance study. Lancet Infect. Dis. 20, 350\u2013361 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"1184_CR181","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1016\/j.vaccine.2010.08.080","volume":"28","author":"JN Liu","year":"2010","unstructured":"Liu, J. N. et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine 28, 7444\u20137451 (2010).","journal-title":"Vaccine"},{"key":"1184_CR182","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1021\/acs.jmedchem.9b01737","volume":"63","author":"B Martinez-Gualda","year":"2020","unstructured":"Martinez-Gualda, B. et al. Scaffold simplification strategy leads to a novel generation of dual human immunodeficiency virus and enterovirus-A71 entry inhibitors. J. Med. Chem. 63, 349\u2013368 (2020).","journal-title":"J. Med. Chem."},{"key":"1184_CR183","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.virusres.2006.12.005","volume":"125","author":"DG Foo","year":"2007","unstructured":"Foo, D. G. et al. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res. 125, 61\u201368 (2007).","journal-title":"Virus Res."},{"key":"1184_CR184","doi-asserted-by":"publisher","first-page":"8376","DOI":"10.1128\/JVI.74.18.8376-8381.2000","volume":"74","author":"BA Lidbury","year":"2000","unstructured":"Lidbury, B. A. & Mahalingam, S. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 74, 8376\u20138381 (2000).","journal-title":"J. Virol."},{"key":"1184_CR185","doi-asserted-by":"publisher","first-page":"13819","DOI":"10.1073\/pnas.202415999","volume":"99","author":"S Mahalingam","year":"2002","unstructured":"Mahalingam, S. & Lidbury, B. A. Suppression of lipopolysaccharide-induced antiviral transcription factor (STAT-1 and NF-kappa B) complexes by antibody-dependent enhancement of macrophage infection by Ross River virus. Proc. Natl. Acad. Sci. USA 99, 13819\u201313824 (2002).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01184-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:50:49Z","timestamp":1757393449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":185,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01184-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"194"}}